证券日报网讯亿帆医药（002019）10月24日在互动平台回答投资者提问时表示，亿立舒美国市场的里程 碑款包括首付款、上市里程碑款及销售里程碑款，收入包括发货收入及销售分成款。 ...

证券日报网讯亿帆医药（002019）10月24日在互动平台回答投资者提问时表示，截至2025年10月20日公 司股东人数为47，150户。 ...

证券日报网讯亿帆医药10月24日在互动平台回答投资者提问时表示，如有重大事项，公司将根据相关规 则及时履行信息披露义务。 （文章来源：证券日报） ...

（编辑 袁冠琳） 证券日报网讯 亿帆医药10月24日在互动平台回答投资者提问时表示，公司目前生产经营一切正常，公 司严格按照法律法规及规范性文件的相关规定进行信息披露工作，不存在应披露而未披露的重大事项， 亦不存在业绩情况提前泄露的情形。 ...

证券日报网讯亿帆医药（002019）10月24日在互动平台回答投资者提问时表示，公司一直以来高度重视 可持续发展，重视环境保护、社会责任及公司治理方面的工作。 ...

证券日报网讯亿帆医药（002019）10月24日在互动平台回答投资者提问时表示，公司始终专注于主营业 务发展，目前经营一切正常，管理层对未来发展充满信心。 ...

Core Viewpoint - Recently, there have been no on-site research activities conducted by institutional investors for Yifan Pharmaceutical (002019.SZ) [1] Company Summary - Yifan Pharmaceutical confirmed on October 22 that there have been no recent on-site research activities by institutional investors [1]

（记者 曾健辉） 亿帆医药（002019.SZ）10月17日在投资者互动平台表示，感谢您的关注与提问。目前还没有收到合作 方的反馈情况。谢谢！ 每经AI快讯，有投资者在投资者互动平台提问：请问F627的美国独家代理商最近反馈三季度在美国的 销售情况如何？是否符合预期或超预期？谢谢！ ...

Core Viewpoint - Yifan Pharmaceutical's stock has shown a year-to-date increase of 31.64%, with recent fluctuations indicating a slight decline over the past 20 and 60 days, suggesting potential volatility in the near term [1][2]. Financial Performance - For the first half of 2025, Yifan Pharmaceutical reported a revenue of 2.635 billion yuan, reflecting a year-on-year growth of 0.11%, while the net profit attributable to shareholders was 304 million yuan, marking a significant increase of 19.91% [2]. - Cumulatively, since its A-share listing, Yifan Pharmaceutical has distributed a total of 1.328 billion yuan in dividends, with 243 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Yifan Pharmaceutical stood at 46,600, a decrease of 0.46% from the previous period, while the average number of circulating shares per person increased by 0.46% to 18,048 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 25.5819 million shares, which is an increase of 2.4783 million shares compared to the previous period [3]. Stock Performance - As of October 15, Yifan Pharmaceutical's stock price was 13.98 yuan per share, with a trading volume of 53.7966 million yuan and a turnover rate of 0.46%, resulting in a total market capitalization of 17.005 billion yuan [1]. - The stock has experienced a net inflow of main funds amounting to 5.0723 million yuan, with significant buying and selling activity from large orders [1].

Core Viewpoint - The transaction between Fangsheng Pharmaceutical and Yifan Pharmaceutical involves the acquisition of the marketing authorization for "Compound Dexamethasone Acetate Cream," which is expected to enhance the company's product portfolio in dermatology and potentially serve as a new profit growth point [1] Group 1: Transaction Details - The contract was signed on September 30, 2025, and does not constitute a related party transaction or a major asset restructuring, falling within the chairman's approval authority [1] - The payment for the transaction will be made in three phases, indicating a structured financial approach to the acquisition [1] Group 2: Market Context - The drug is used for various skin diseases, with 103 companies in China holding production licenses for it [1] - In the first half of 2025, the sales revenue from physical pharmacies for this drug reached 175 million yuan, highlighting its market potential [1] Group 3: Strategic Implications - The acquisition aligns with the company's development strategy to expand its dermatological product offerings, which is expected to contribute positively to future revenue streams [1] - However, the timeline for completing the holder change procedures remains uncertain, and sales may be influenced by market factors, necessitating cautious decision-making by investors [1]